Introduction: We investigated the potential impact of stage migration because of positron-emission tomography (PET) scan staging on survival in the locally advanced (stage IIIA/ B) NSCLC setting.
Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide. NSCLC accounts for 80% to 85% of cases of lung cancer, of which one-third have locally advanced disease at diagnosis. 1, 2 Currently, concurrent chemoradiotherapy is the standard treatment for locally advanced stage III NSCLC in patients with a good performance status (PS). [3] [4] [5] However, there is a need for more effective and less toxic regimens as the 5-year survival rates remain low (approximately 14% for stage IIIA and 5% for stage IIIB NSCLC). 2, 6 In the PROCLAIM phase 3 trial, concurrent pemetrexed plus cisplatin and thoracic radiotherapy (TRT) followed by consolidation pemetrexed (arm A) in stage IIIA/B inoperable NSCLC did not show superior survival versus a standard concurrent chemoradiotherapy with consolidation (etoposide; arm B). 7 Both treatment arms had longer than expected median overall survival (OS) compared to historical data. Statistical assumptions at the study design anticipated a median OS of approximately 18 months in the control arm (arm B) with a 6-month improvement in the experimental arm (arm A), and median OS exceeded 24 months in both treatment arms.
Fluoro-2-deoxyglucose positron-emission tomography (FDG-PET, from here on referred to as PET scan) scan has emerged as a useful tool in the clinical management of lung cancer because of its accuracy in diagnosis, staging, and evaluation of response to anticancer treatments. 8, 9 In 2003, the American Society of Clinical Oncology recommended the complementary use of PET scan to/with computed tomography for patients with nonmetastatic NCSLC. 10 Because PET scan allows more accurate staging of locally advanced NSCLC with its better ability to define intrathoracic nodal disease for radiotherapy planning and detection of metastatic disease unrecognized by conventional staging, it is now routinely incorporated into staging algorithms.
Currently, disease stage is one of the most important prognostic factors for survival in NSCLC together with PS. [11] [12] [13] The use of baseline PET scan in a population might result in shifting of patients with early-stage lung cancer into higher stages, a phenomenon known as stage migration. 14, 15 Prior studies have established that initial PET scan use at diagnosis impacts staging and treatment management plan, and thus may have a prognostic value in NSCLC. 16, 17 Previous single-institution data suggested evidence of a significant impact of PET scans on survival outcomes due to stage migration. 17 The potential impact of stage migration because of PET scan staging on survival has rarely been measured in randomized trials in the locally advanced (stage IIIA/B) NSCLC setting. We report the results of OS and progression-free survival (PFS) from a subgroup analysis of the first-ever nested series of patients in a phase 3 trial who did, and did not, undergo a baseline PET scan.
Methods

Study Design and Patient Population
The PROCLAIM trial was conducted at 126 centers in 21 countries between October 2008 and November 2014. 7, 18 Eligible patients were stratified by baseline PS, gender, disease stage, and PET scan, and were randomized (1:1) to one of two arms. Patients either received pemetrexed (500 mg/m 2 intravenously) followed by cisplatin (75 mg/m 2 intravenously) every 3 weeks for 3 cycles plus concurrent TRT (60 to 66 Gy) followed by 4 cycles of consolidation pemetrexed (500 mg/m 2 intravenously every 3 weeks) or received etoposide (50 mg/ m 2 intravenously) on days 1 through 5 every 4 weeks followed by cisplatin (50 mg/m 2 ) on days 1 and 8 for 2 cycles plus concurrent TRT, followed by 2 cycles of a platinum-based doublet regimen of choice as consolidation treatment: etoposide-cisplatin (same dose and schedule as during concurrent treatment) or vinorelbine (30 mg/m 2 intravenously) on days 1 and 8 every 3 weeks and cisplatin (75 mg/m 2 ) on day 1 every 3 weeks (vinorelbine-cisplatin) or paclitaxel (200 mg/m 2 ) intravenously on day 1 every 3 weeks followed by intravenous administration of carboplatin at area under the concentration-time curve (AUC ¼ 6) on day 1 every 3 weeks (paclitaxel-carboplatin). Radiotherapy was administered as previously described.
In the PROCLAIM study, PET scan staging was one of the stratification factors as its use was not a protocol requirement due to varying access to PET scans in the participating countries when the study began. PET scans were performed according to the local practice of the participating site. The primary objective was OS analysis, whereas a secondary objective was PFS analysis. The survival analyses of patients who did, and did not, undergo a staging PET scan was a post hoc subgroup analysis based on the intent-to-treat (ITT) population (598 patients) with stage IIIA/B nonsquamous NSCLC randomized to either pemetrexed-cisplatin (arm A) or etoposide-cisplatin (arm B). Subgroup analyses by PET scan use were performed for each treatment arm to assess a potential differential effect of PET staging based on treatment. The study used American Joint Committee on Cancer TNM staging for lung cancer (6th edition, 2002). The study was not powered for this subgroup analysis.
Statistical Analysis and Assessment
Kaplan-Meier methods and Cox regression models were used to estimate hazard ratios (HRs). OS was measured from the date of randomization to the date of death from any cause. PFS was defined as the time from the date of random assignment to the first date of documented objective progressive disease (Response Evaluation Criteria in Solid Tumors v1.0) or death from any cause.
Results
Of the 598 patients randomized to either arm, 491 (82.1%) had PET scan staging performed (83.1% in arm A and 81.1% in arm B). The patient tumor baseline characteristics are presented in Table 1 . Patient and disease characteristics were generally well balanced between the two subgroups (PET scan-staged patients and patients without PET scans). There was a higher proportion of Whites (77% versus 42%) and stage IIIA patients (49% versus 39%) in the subgroup with PET scan use. The descriptive population allocation by race and geography is presented in Table 1 . Overall, most patients enrolled in European Union (EU), North America, and Australia had PET scan staging performed (range, 88% to 93%); whereas in South America and Asia, the use of a PET scan was less frequent with none and 59% of patients in the PET Yes group, respectively.
In the ITT population, median OS was 27. Table 3 ) were observed for patients with PET scans compared to those with conventional staging in both treatment arms, consistent with the ITT population analysis. Relapse at distant disease was higher for patients with the PET-Yes group versus the PET-No group (data not given).
Discussion
The use of PET scan for the staging of patients diagnosed with NSCLC, especially for stage I to III (when no metastatic sites have been identified), has been progressively adopted in clinical practice since 2003. 19, 20 In recent trials, such as PROCLAIM and RTOG 0617, PET scan staging was used in a majority of the patients (82% and 91%, respectively), and both studies showed higher median OS than historical trials in locally advanced NSCLC. 7, 20 Improved outcomes of stage III NSCLC patients reported in current trials compared with previous trials 7, 20 may result from stage migration because of the increased use of PET scans and magnetic resonance imaging of the brain. However, this hypothesis has not been evaluated in the context of a large phase 3 trial.
Results from a subgroup analysis of PET-scan staged patients and patients without PET scans from the PRO-CLAIM trial showed that the risk of death in patients with PET scan staging was 19% lower than in patients with conventional staging, although the 6.4-month increase in median OS for the patients with PET-scan staging was not statistically significant. Patients with PET-scan staging had a 27% lower risk of progression and a statistically significant improvement of 2.1 months in median PFS compared to those with conventional staging. Subgroup analyses for each treatment arm were consistent with those of the ITT population, confirming the impact of PET-scan staging on survival outcomes was independent of treatment. These findings support the hypothesis that better OS and PFS reported in recently completed trials is likely, in part, due to the higher use of PET scan staging in the past few years.
The PET-scan-staged patients group had a higher proportion of white and stage IIIA patients. The higher proportion of white ethnicity versus other ethnicities in this subgroup can be explained by the higher adoption/ use of PET scan staging in EU countries and North America (>90%), the main contributing regions to enrollment, compared to Asia where only approximately 59% of patients had a PET scan performed while the study was enrolling patients. Survival for the PET-scan-staged Asian population in the PROCLAIM trial had median OS rates similar to the PET-scan-staged EU and ITT populations, suggesting that the Asian population did not receive inferior treatment. However, the survival analyses did not control for any other geographic variations of treatment.
The impact of PET staging was investigated retrospectively using a database of 700 patients treated with stereotactic body radiotherapy for lung metastases in 20 centers in Germany and Switzerland between 1997 and 
2014
. 21 Of the 700 patients, 230 (32.9%) had PET scan staging performed. A significantly improved 1-year and 2-year (82.7% and 64.8%, respectively) OS was observed in PET-scan-staged patients as compared to patients without PET staging (72.8% and 52.6%, respectively) (p ¼ 0.012). 21 The authors of the publication attribute the significant effect of FDG-PET staging on OS to better patient selection. 21 Prior studies have shown disease stage and PS to be prominent prognostic factors in NSCLC. 22 Besides its prognostic value, staging is of great importance in deciding the treatment plan. 23 Data from this study show a higher proportion of stage IIIA patients in the PETscan-staged patients group, suggesting that some of the stage IIIB patients in this group would have been upstaged to stage IV thus reducing the proportion of stage IIIB patients. It is also possible that some of the stage II patients by conventional staging were upstaged to IIIA after PET staging, thus enriching the IIIA population. The migration would improve the survival in the assigned arm because fewer patients with metastasis would be assigned to that arm. Eastern Cooperative Oncology Group (ECOG) PS was well balanced between the two groups, thus excluding a differential effect on survival.
These results support the hypothesis that better survival outcomes in the PET-scan-staged patients group is likely associated with stage migration although we do not have direct evidence of upstaging in the PET-scan group. More importantly, from a research perspective, our results strongly encourage studies to use PET scans routinely or, if not able to do so, attempt to control for the impact on outcomes by controlling for any variability that their use, or nonuse, might induce. Furthermore, the results from a clinical perspective highlight the value of PET scans to ensure, as much as possible, therapies with curative potential but with any risk are undertaken only when optimal evaluation of the stage can be obtained. Even when the disease staging is correct, PET scans might allow for better definition of the target volume for radiation, avoiding geographic misses that could lead to lower PFS and OS.
Because this was an exploratory analysis, future prospective analyses are required to further validate the findings. Nevertheless, this is the first-ever attempt to measure this impact in a phase 3 trial and the results support the prognostic value of PET scan staging for better outcomes.
Conclusions
The patient subgroup with PET scans showed a significantly improved PFS and a numerically longer OS as compared to patients with conventional staging, regardless of treatment. These findings are consistent with improved survival due to stage migration. The magnitude of differences in OS and PFS based on PET scan is a reminder of the potential of factors other than the therapeutic intervention to affect outcomes.
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